AU2003256983A1 - Compositions comprising polysaturated fatty acid (pufas) for the control of appetite and body weight management - Google Patents

Compositions comprising polysaturated fatty acid (pufas) for the control of appetite and body weight management

Info

Publication number
AU2003256983A1
AU2003256983A1 AU2003256983A AU2003256983A AU2003256983A1 AU 2003256983 A1 AU2003256983 A1 AU 2003256983A1 AU 2003256983 A AU2003256983 A AU 2003256983A AU 2003256983 A AU2003256983 A AU 2003256983A AU 2003256983 A1 AU2003256983 A1 AU 2003256983A1
Authority
AU
Australia
Prior art keywords
pufas
appetite
compositions
fatty acid
control
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003256983A
Inventor
Nancy A. Auestad
Yung-Sheng Huang
Tina D. Wolf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of AU2003256983A1 publication Critical patent/AU2003256983A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003256983A 2002-08-06 2003-07-30 Compositions comprising polysaturated fatty acid (pufas) for the control of appetite and body weight management Abandoned AU2003256983A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40146602P 2002-08-06 2002-08-06
US60/401,466 2002-08-06
PCT/US2003/023708 WO2004012727A1 (en) 2002-08-06 2003-07-30 Compositions comprising polysaturated fatty acid (pufas) for the control of appetite and body weight management

Publications (1)

Publication Number Publication Date
AU2003256983A1 true AU2003256983A1 (en) 2004-02-23

Family

ID=31495965

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003256983A Abandoned AU2003256983A1 (en) 2002-08-06 2003-07-30 Compositions comprising polysaturated fatty acid (pufas) for the control of appetite and body weight management

Country Status (4)

Country Link
AR (1) AR040810A1 (en)
AU (1) AU2003256983A1 (en)
TW (1) TW200412942A (en)
WO (1) WO2004012727A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR046132A1 (en) * 2003-10-24 2005-11-23 Solvay Pharm Gmbh PHARMACEUTICAL COMPOSITION CONTAINING AT LEAST ONE COMPOUND WITH RECEIVER ACTIVITY OF CB1, OR A PROFARMACO, TAUTOMERO OR SALT OF THE SAME, AS A SUITABLE ACTIVE COMPONENT FOR THE TREATMENT AND / OR PROFILAXIS OF DISEASES RELATED TO THE RECEIVER CB1 IN PATIENTS OR YOUTH PATIENTS THE TREATMENT
CN1867332A (en) * 2003-10-24 2006-11-22 索尔瓦药物有限公司 Combination treatment of obesity involving selective cb1-antagonists and lipase inhibitors
RU2006117627A (en) * 2003-10-24 2007-12-10 Зольвай Фармасьютиклз Гмбх (De) NEW APPLICATIONS IN MEDICINE OF COMPOUNDS WITH ANTAGONISTIC ACTIVITY RELATING TO CB1, AND COMBINED TREATMENT USING THESE COMPOUNDS
SE0303513D0 (en) 2003-12-19 2003-12-19 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and any or any combination thereof
JP2008517976A (en) 2004-10-25 2008-05-29 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング A pharmaceutical composition for the treatment of diabetes mellitus type 1, obesity and related symptoms, comprising a CB1 cannabinoid receptor antagonist and a potassium channel opener
CN103058867B (en) 2005-05-04 2015-03-25 普罗诺瓦生物医药挪威公司 Novel DHA derivatives for and uses thereof as medicament
KR20080103972A (en) * 2006-02-28 2008-11-28 브리스톨-마이어스스퀴브컴파니 Use of DA and AL in the manufacture of a composition for the prevention or treatment of obesity
WO2007100562A2 (en) * 2006-02-28 2007-09-07 Bristol-Myers Squibb Company Use of dha and ara in the preparation of a composition for reducing triglyceride levels
EP1886680A1 (en) * 2006-05-23 2008-02-13 Nestec S.A. Maternal supplement
US9066915B2 (en) 2006-10-03 2015-06-30 Michael D. Myers Meal replacement compositions and weight control method
EP2094640A4 (en) 2006-11-01 2015-05-20 Pronova Biopharma Norge As Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (ppar).
WO2010018856A1 (en) * 2008-08-13 2010-02-18 持田製薬株式会社 Prophylactic/ameliorating or therapeutic agent for cannabinoid receptor-related disease
PL2353595T3 (en) 2010-01-19 2016-03-31 Mjn Us Holdings Llc Nutritional compensation for western-type diet
US10251928B2 (en) 2014-11-06 2019-04-09 Mead Johnson Nutrition Company Nutritional supplements containing a peptide component and uses thereof
US11109607B2 (en) 2013-11-18 2021-09-07 Gary Hall Oil-based compositions for enhancing oral health and general wellness in humans
EP4017874A1 (en) 2019-08-21 2022-06-29 Coda Biotherapeutics, Inc. Compositions and methods for neurological diseases
WO2024036227A2 (en) * 2022-08-11 2024-02-15 Helaina Inc. Edible composition comprising recombinant human secretory protein

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0813776B2 (en) * 1990-08-10 1996-02-14 株式会社資生堂 Method for separating and purifying docosahexaenoic acid compound
US5578334A (en) * 1995-04-07 1996-11-26 Brandeis University Increasing the HDL level and the HDL/LDL ratio in human serum with fat blends
US6428832B2 (en) * 1996-03-26 2002-08-06 Dsm N.V. Late addition of PUFA in infant formula preparation process
EP0843972B1 (en) * 1996-11-20 2002-07-31 N.V. Nutricia Nutritional composition comprising fats for the treatment of the metabolic syndrome
US6495599B2 (en) * 2000-04-13 2002-12-17 Abbott Laboratories Infant formulas containing long-chain polyunsaturated fatty acids and uses therof
US7025984B1 (en) * 2000-06-26 2006-04-11 The Procter & Gamble Company Compositions and methods for body weight management
IT1320180B1 (en) * 2000-12-29 2003-11-26 Hunza Di Marazzita Maria Carme NUTRITIONAL AND THERAPEUTIC PREPARATIONS EQUIPPED WITH ANTI-OXIDANT ACTIVITY AND ABLE TO CONTROL THE PONDERAL EXCESSES AND

Also Published As

Publication number Publication date
AR040810A1 (en) 2005-04-20
WO2004012727A1 (en) 2004-02-12
TW200412942A (en) 2004-08-01

Similar Documents

Publication Publication Date Title
AU2003256983A1 (en) Compositions comprising polysaturated fatty acid (pufas) for the control of appetite and body weight management
AU2003288686A8 (en) Compositions and systems for the regulation of genes
WO2003072035A8 (en) Compositions and methods for the treatment of immune related diseases
AU2003201693A1 (en) Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
AU2003260934A1 (en) An apparatus for the application of a curable composition to a fastener and curable compositions suitable for application to a fastener
AU2003237571A1 (en) Method and system for controlling the development of biological entities
AU2003252305A1 (en) Composition for preparation for external use on skin and method of using the same
AU2003304576A1 (en) Cis-hydrogenated fatty acid coating of medical devices
AU2003293967A1 (en) Cholesterol-reducing agent containing an n-3 fatty acid
AU2003222083A1 (en) Acid and ester compounds and methods of using the same
AU2003247351A1 (en) Anti-acne compositions and methods of use
AU2003213663A1 (en) Methods and compositions for regulating adipogenesis
AU2003234128A1 (en) Compositions and methods for regulation of plant gamma-tocopherol methyltransferase
AU2003282755A1 (en) Methods of regulating body weight
AU2003225956A1 (en) Apparatus for automatic application of compositions to the skin
AU2003219614A1 (en) Combination of flavonoid and procyanidin for the reduction of the mammalian appetite
AU2003295107A1 (en) Biological control agent and formulations
AU2003265914A1 (en) Shear modification of hdpe-clay nanocomposites
AU2003294684A1 (en) Ketoprofen compositions and methods of making them
AU2003300543A1 (en) Slow release formulation of clarithromycin
ZA200409498B (en) Use of new etonogestrel esters
AU2003298441A1 (en) Biological control agent and formulations
AU2003209999A1 (en) Wax and candle compositions
AU2003212866A1 (en) Controlled release compositions and methods for using same
AU2003297906A1 (en) Modulation of interleukin 18 expression

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase